Login / Signup

Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.

Chad R SchultzMatthew A SwansonThomas C DowlingAndré S Bachmann
Published in: Cancer chemotherapy and pharmacology (2021)
Addition of probenecid as an adjuvant to DFMO therapy may be suitable to decrease overall dose and improve drug efficacy in vivo.
Keyphrases
  • early stage
  • emergency department
  • stem cells
  • drug induced
  • bone marrow